Shopping Cart
Remove All
Your shopping cart is currently empty
EGFRkinase inhibitor 5 (Compound 4c) is an orally active epidermal growth factor receptor (EGFR) kinase inhibitor with an IC50 of 18.35 μM. It induces apoptosis and exhibits anticancer and anti-inflammatory properties while maintaining low toxicity (LD50 range of 500-2000 mg/kg).
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 10 mg | Inquiry | Backorder | Backorder | |
| 50 mg | Inquiry | Backorder | Backorder |
| Description | EGFRkinase inhibitor 5 (Compound 4c) is an orally active epidermal growth factor receptor (EGFR) kinase inhibitor with an IC50 of 18.35 μM. It induces apoptosis and exhibits anticancer and anti-inflammatory properties while maintaining low toxicity (LD50 range of 500-2000 mg/kg). |
| In vitro | EGFR kinase inhibitor 5 (0-80 μM, 72 h) hinders the migration of A549 cancer cells and suppresses the activity of A549, MCF7, and HCT116 cancer cells, with IC₅₀ values of 10.74, 18.73, and 23.22 μM, respectively. |
| In vivo | EGFR kinase inhibitor 5 (14.77 mg/kg, oral, 15 days) exhibits anti-inflammatory activity in a carrageenan-induced rat paw edema model, and it has a low tendency to cause ulcer formation and lipid peroxidation. |
| Formula | C21H16BrN3OS2 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.